Fulcrum Therapeutics Statistics
Share Statistics
Fulcrum Therapeutics has 53.98M
shares outstanding. The number of shares has increased by -13.15%
in one year.
| Shares Outstanding | 53.98M |
| Shares Change (YoY) | -13.15% |
| Shares Change (QoQ) | 0.08% |
| Owned by Institutions (%) | 82.74% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 975 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 3.56M, so 6.6% of the outstanding
shares have been sold short.
| Short Interest | 3.56M |
| Short % of Shares Out | 6.6% |
| Short % of Float | 8.55% |
| Short Ratio (days to cover) | 10.71 |
Valuation Ratios
The PE ratio is -29.96 and the forward
PE ratio is null.
Fulcrum Therapeutics's PEG ratio is
0.34.
| PE Ratio | -29.96 |
| Forward PE | n/a |
| PS Ratio | 3.64 |
| Forward PS | 3.6 |
| PB Ratio | 1.2 |
| P/FCF Ratio | -116.72 |
| PEG Ratio | 0.34 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Fulcrum Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.63,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 22.63 |
| Quick Ratio | 22.63 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.47 |
| Debt / FCF | -3.46 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,777,777.78 |
| Profits Per Employee | $-216,111.11 |
| Employee Count | 45 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -27.6% in the
last 52 weeks. The beta is 2.29, so Fulcrum Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.29 |
| 52-Week Price Change | -27.6% |
| 50-Day Moving Average | 3.37 |
| 200-Day Moving Average | 4.59 |
| Relative Strength Index (RSI) | 72.73 |
| Average Volume (20 Days) | 504,401 |
Income Statement
In the last 12 months, Fulcrum Therapeutics had revenue of 80M
and earned -9.72M
in profits. Earnings per share was -0.17.
| Revenue | 80M |
| Gross Profit | 78.41M |
| Operating Income | -21.9M |
| Net Income | -9.72M |
| EBITDA | -18.24M |
| EBIT | -19.83M |
| Earnings Per Share (EPS) | -0.17 |
Full Income StatementBalance Sheet
The company has 58.21M in cash and 8.63M in
debt, giving a net cash position of 49.58M.
| Cash & Cash Equivalents | 58.21M |
| Total Debt | 8.63M |
| Net Cash | 49.58M |
| Retained Earnings | -519.4M |
| Total Assets | 242.65M |
| Working Capital | 224.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -2.22M
and capital expenditures -278K, giving a free cash flow of -2.5M.
| Operating Cash Flow | -2.22M |
| Capital Expenditures | -278K |
| Free Cash Flow | -2.5M |
| FCF Per Share | -0.04 |
Full Cash Flow StatementMargins
Gross margin is 98.01%, with operating and profit margins of -27.37% and -12.16%.
| Gross Margin | 98.01% |
| Operating Margin | -27.37% |
| Pretax Margin | -12.16% |
| Profit Margin | -12.16% |
| EBITDA Margin | -22.8% |
| EBIT Margin | -27.37% |
| FCF Margin | -3.12% |
